Please login to the form below

Cytokinetics

This page shows the latest Cytokinetics news and features for those working in and with pharma, biotech and healthcare.

Prior to joining Genetech Sabry was chief executive officer for start-up biotech and was founder and chief executive of biopharma Cytokinetics.

Amgen agrees to take Cytokinetics' heart failure drug into phase III

originator, Cytokinetics, which has been waiting for the big biotech to make a decision for several weeks. ... Cytokinetics said recently that meetings have been held with both the FDA and EMA to discuss the design of the outcomes study, which is due to
Biogen buys into Ionis' nusinersen after positive phase III trial

Potential blockbuster spinal muscular atrophy drug will be filed “in the coming months” 
Roche buys rare disease firm Trophos in €470m deal

SMA therapy in development at Cytokinetics, while Biogen Idec and Isis Pharmaceuticals are also developing ISIS-SMNRx for the disease, a drug due to enter phase III soon.
Astellas forges $675m muscle alliance with Cytokinetics

Extendscollaboration to include neuromuscular diseases. Astellas has signed a major expansion of its collaboration with US biotech Cytokinetics to include neuromuscular diseases. ... It works in a similar way to Cytokinetics' tirasemtiv which is already
Amgen drug misses endpoint in acute heart failure trial

A drug in development by Amgen and Cytokinetics to treat symptoms of heart failure has missed its primary endpoint in a phase II trial.

More from news
Approximately 4 fully matching, plus 4 partially matching documents found.

Deal Watch February 2017

Sale of Priority Review Voucher (PRV). 125. Cytokinetics/ Royalty Pharma. 4.5% royalty on global sales of omecamtiv mecarbil for heart failure (phase III).
Deal Watch July 2016

Real Relationships. Astellas and Cytokinetics have announced another extension to their agreement involving the development of their skeletal muscle activators, tirasemtiv and CK-2127107. ... 181. Cytokinetics/ Astellas. Tirasemtiv, CK-2127107 and
Astellas: Ten years young

option, while in muscle disease Astellas is working with Californian clinical-stage biopharmaceutical company Cytokinetics, looking at mechanisms for improving muscle strength.
Heart failure therapy embarks on a new era

In collaboration with Cytokinetics, Amgen is developing omecamtiv mecarbil, an activator of cardiac myosin that is designed to increase the duration of cardiac muscle contractility and improve cardiac muscle performance.
Deal Watch table for December 2014

Licence. 700. Cytokinetics / Astellas Pharma. CK-2127107, fast skeletal troponin activator, in Spinal Muscular Atrophy and other neuromuscular indications (p1).

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Client Services Director – Medical Education Agency – North West...: Salary TBC

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Engagement Expert, Healthcare Brand Communications, London: Excellent package

Senior Account Manager, Rare Diseases – Medical Communications, ...: Excellent package

Senior Account Director development role to Business Director, H...: Excellent package

Global Business Development Director – Health Education: excellent commission

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Add my company

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Unlocking the potential of science and technology in the UK: Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints: What to expect from 2019...
Not another weight-loss ad: Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...